ARCHIVES

Genentech Reps Not Welcome: Hospitals Urge Drug Maker to Reverse Policy On Supplying Avastin, Rituxan, & Herceptin

This article is from The Cancer Letter archive.

Vol. 40 No. 39 | October 17, 2014

Download PDF Visit The Full Archive

Related Articles

CMX001 Reduces Adenovirus Progression and Viremia

August 30, 2013

Possible Government Shutdown Looms Over Biomedical Research Funding Once More

September 23, 2011

European Agency Recommends Transfusions Over ESAs For Cancer Patients With Longer Life Expectancy.

June 27, 2008

Zometa Reduced Bone Complications In Patients With Prostate Cancer Bone Mets

October 25, 2002

NCI Programs: Institute To Expand Career Development, Training Grants

December 18, 1998

Phase III Study Evaluating Halaven Fails To Meet Primary Endpoints

July 27, 2012